About the Company

Medeia Therapeutics Ltd., founded in 2006, is a private biotechnology company dedicated to discover and develop completely new therapeutic approaches for diseases with high unmet medical needs.

Medeia’s focus areas include the discovery , preclinical research and early development of novel therapeutics. Our R&D programs aim at developing therapeutics for life-threatening conditions of the elderly, focusing especially on serious neurological diseases such as Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis and other degenerative diseases. Our R&D pipeline consists of both small molecule and cell-based therapeutic approaches.

Medeia operates under a semi-virtual business model- we outsource all non-core business functions while retaining seamless control over key technology assets, strategic partnerships and financial management with a small core group of highly experienced employees.